/C O R R E C T I O N -- Aethlon Medical, Inc./

                /C O R R E C T I O N -- Aethlon Medical, Inc./

PR Newswire

SAN DIEGO, Jan. 29, 2013

In the news release, Aethlon Medical Discloses CEO Interview, issued
29-Jan-2013 by Aethlon Medical, Inc. over PR Newswire, the embedded hyperlink
in the second paragraph, second sentence, should read
"http://bit.ly/UTSanDiego-BrianBrittShow-JimJoyce-Aethlon". The complete,
corrected release follows:

  Aethlon Medical Discloses CEO Interview

SAN DIEGO, Jan. 29, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD),
today disclosed that a recent interview our Chairman and CEO, Jim Joyce
participated in with the UT San Diego radio network is now available on-line.

Mr. Joyce was interviewed on the Brian Britt Show which is broadcast on the UT
San Diego radio network. The interview is available at
http://bit.ly/UTSanDiego-BrianBrittShow-JimJoyce-Aethlon. Part one of the
interview is on podcast number 03 and the second part is on podcast number 04.

About Aethlon Medical

Aethlon Medical creates innovative medical devices that address unmet medical
needs in cancer, infectious disease, and other life-threatening conditions.
Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides
the basis for a new class of devices the rapid, yet selective removal of
disease promoting particles from the entire circulatory system. At present,
The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to
address infectious disease and cancer, and a medical device being developed
under a 5-year contract with Defense Advanced Research Projects Agency (DARPA)
to reduce the incidence of sepsis in combat-injured soldiers. For more
information, please visit www.aethlonmedical.com.

About The Aethlon Hemopurifier®

The Aethlon Hemopurifier® is a first-in-class medical device that selectively
targets the rapid clearance of infectious viral pathogens and
immunosuppressive proteins from the entire circulatory system. In the
treatment of Hepatitis C virus (HCV), human studies have demonstrated that
Hemopurifier® therapy may improve immediate, rapid and sustained virologic
response rates when administered in the first few days of standard-of-care
drug therapy. In addition to accelerating viral load depletion,
post-treatment analysis of the Hemopurifier® has documented the capture of up
to 300 billion HCV copies of HCV during a single six-hour treatment. Access
to Hemopurifier® therapy is available on a compassionate-use basis through the
Medanta Medicity Institute (Medicity), a leading center for medical tourism in
India. The Medicity is offering treatment access to infected individuals who
previously failed or subsequently relapsed standard-of-care drug regimens.
The Hemopurifier® is also being offered as a salvage therapy to infected
individuals who suffer a viral breakthrough during standard-of-care therapy.
U.S. studies of the Hemopurifier® are currently pending approval of an IDE
submitted to FDA. 

The Aethlon Hemopurifier® and Cancer

In addition to the opportunity to address a broad-spectrum of infectious viral
pathogens, the Hemopurifier® has been discovered to capture tumor-derived
exosomes underlying several forms of cancer. Tumor-derived exosomes have
recently emerged to be a vital therapeutic target in cancer care. These
microvesicular particles suppress the immune response in cancer patients
through apoptosis of immune cells and their quantity in circulation correlates
directly with disease progression. Beyond possessing immunosuppressive
properties, tumor-derived exosomes facilitate tumor growth, metastasis, and
the development of drug resistance. By addressing this unmet medical need,
the Hemopurifier® is positioned as an adjunct to improve established cancer
treatment regimens.

Certain statements herein may be forward-looking and involve risks and
uncertainties. Such forward-looking statements involve assumptions, known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Aethlon Medical, Inc. to be materially
different from any future results, performance, or achievements expressed or
implied by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, that the FDA will not approve the
initiation of the Company's clinical programs or provide market clearance of
the company's products, future human studies whether revenue or non-revenue
generating from either compassionate use or non-compassionate use of the
Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to
improve patient responsiveness to established cancer or hepatitis C therapies
or sepsis therapies or as a standalone cancer or hepatitis C therapy or
standalone sepsis therapy, the Company's ability to raise capital when needed,
the Company's ability to complete the development of its planned products, the
Company's ability to manufacture its products either internally or through
outside companies and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology,
product liability exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. In such instances, actual
results could differ materially as a result of a variety of factors, including
the risks associated with the effect of changing economic conditions and other
risk factors detailed in the Company's Securities and Exchange Commission
filings. The Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events, or otherwise.


James A. Joyce
Chairman and CEO
858.459.7800 x301

Jim Frakes
Chief Financial Officer
858.459.7800 x300

Marc Robins

SOURCE Aethlon Medical, Inc.

Website: http://www.aethlonmedical.com
Press spacebar to pause and continue. Press esc to stop.